Conference Reports for NATAP

13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil Back

High efficacy of twice-yearly subcutaneous lenacapavir for PrEP through 52 weeks of open-label extension in PURPOSE 2       IAS 2026 Rio, Brazil   M. LOSSO   IAS: Favorable Tolerability of Lenacapavir for PrEP Administered at Participant-Chosen Anatomic Sites in PURPOSE 1 and PURPOSE 2 - (07/31/26)